
Gilead signs royalty-free licensing agreements with three generic manufacturers to expand future access to its investigational antiviral obeldesivir.
Once a niche pilot, direct-to-patient drug distribution is now a defining strategic priority, with manufacturers building the right infrastructure standing to capture margin, data, and patient relationships that used to belong to intermediaries.
Once viewed as an experimental approach reserved for niche therapies, direct-to-patient (DTP) drug distribution is rapidly becoming one of the most consequential strategic shifts in modern pharmaceuticals.




